BCM
KROS icon

Bridgeway Capital Management’s Keros Therapeutics KROS Stock Holding History

Bridgeway Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Buy
195,017
+134,939
+225% +$2.08M 0.04% 511
2025
Q4 		$1.22M Buy
+60,078
New +$1.05M 0.03% 665

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Bridgeway Capital Management's KROS Position: Q1 2026 in Review

Bridgeway Capital Management increased its Keros Therapeutics (KROS) stake by 225% in Q1 2026, buying an estimated $2.08M and bringing the position to 195,017 shares worth $2.15M. The position accounts for 0.04% of the portfolio, ranked #511.

Bridgeway Capital Management first reported a position in KROS in Q4 2025 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Bridgeway Capital Management held 195,017 shares of Keros Therapeutics worth $2.15M as of Q1 2026.
  • Bridgeway Capital Management bought 134,939 Keros Therapeutics shares in Q1 2026, an estimated $2.08M.
  • Keros Therapeutics made up 0.04% of Bridgeway Capital Management's portfolio in Q1 2026, its #511 holding.
  • Bridgeway Capital Management first reported a position in Keros Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.